PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12815339

Proteomics.

John M Arthur
View original source ↗Export metadata ↓

Abstract

PURPOSE OF REVIEW: Proteomics encompasses a group of technologies that attempt to separate, identify and characterize a global set of proteins. This review will highlight the technologies available, outline the capabilities, advantages and disadvantages of each and briefly describe applications in nephrology. RECENT FINDINGS: Proteomics provides information about abundance, location, chemical modification and protein-protein interactions that is not available from genomic technologies. Several proteomic approaches are now widely available. Liquid chromatography/mass spectrometry, two-dimensional gel electrophoresis, antibody arrays and protein chips (surface enhanced laser desorption ionization) provide opportunities to identify and compare an abundance of proteins as well as to determine posttranslational modifications, subcellular location and molecular interactions. Recent advances such as multidimensional chromatographic analysis and isotope coded affinity tags have expanded the usefulness of these approaches. SUMMARY: Proteomic technologies are improving and developing rapidly. These techniques will be valuable tools to develop markers for disease, identify and evaluate proteins as drug targets and understand renal physiology at the protein level.

Explore related subjects

AntibodiesChromatography, LiquidElectrophoresis, Gel, Two-DimensionalHumansKidney DiseasesMass SpectrometryProtein Array AnalysisProteinsProteomicsJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

John M Arthur. 2003. Proteomics.. https://doi.org/10.1097/00041552-200307000-00011

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2021

ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.

In glioblastoma (GBM), the most frequent and lethal brain tumor, therapies suppressing recurrently altered signaling pathways failed to extend survival. However, in patient subsets, specific genetic lesions can confer sensitivity to targeted agents. By exploiting an integrated model based on patient-derived stem-like cells, faithfully recapitulating the original GBMs in vitro and in vivo, here, we identify a human GBM subset (∼9% of all GBMs) characterized by ERBB3 overexpression and nuclear accumulation. ERBB3 overexpression is driven by inheritable promoter methylation or post-transcriptional silencing of the oncosuppressor miR-205 and sustains the malignant phenotype. Overexpressed ERBB3 behaves as a specific signaling platform for fibroblast growth factor receptor (FGFR), driving PI3K/AKT/mTOR pathway hyperactivation, and overall metabolic upregulation. As a result, ERBB3 inhibition by specific antibodies is lethal for GBM stem-like cells and xenotransplants. These findings highlight a subset of patients eligible for ERBB3-targeted therapy.

Antibodies↗
PubMed2003

Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signalling.

Cisplatin-selected cervix carcinoma HeLa cell lines induced less apoptosis, and weaker activation by cisplatin or Fas-activating antibody, of mitochondrial-associated caspase-9 and death receptor-mediated caspase-8 than did parental cells. Furthermore, less DISC (death-inducing signalling complex) was formed in cisplatin-selected cell lines than in parental cells. Ac-IETD-CHO (acetyl-Ile-Glu-Thr-Asp-aldehyde), which has a certain preference for inhibiting caspase-8, or Fas-antagonistic antibody, significantly inhibited cisplatin-induced apoptosis in both parental and cisplatin-selected HeLa cell lines. These results imply that cell-surface death signalling is inducible by cisplatin; that reduction of this pathway is associated with drug resistance, and that cisplatin-selected cells acquire cross-resistance to cell-surface death signalling. Sequential up-regulation of FLIP (FLICE-like inhibitory protein), but not Bcl-2, Bcl-x(L) or inhibitors of apoptosis protein (IAPs), was observed in resistant cells but not in parental cells. The inhibition of FLIP by FLIP antisense oligonucleotides promotes cisplatin and Fas-antibody-induced apoptosis. However, the modulation of apoptosis by FLIP antisense oligonucleotides in resistant cells is greater than that in parental cells. The presented data reveal that the up-regulation of FLIP may contribute to the suppression of apoptosis and thereby change cells that are resistant to cisplatin and Fas-mediated death signals. The results also show that cancer cells that have undergone long-term chemotherapy and become chemoresistant may change the FLIP level, becoming cross-resistant to death factors such as Fas.

Antibodies↗
PubMed2003

A surface plasmon resonance probe with a novel integrated reference sensor surface.

A surface plasmon resonance (SPR) sensor probe with integrated reference surface is described. In order to fabricate the integrated reference surface, two dielectric layers with different thickness were deposited on the single gold SPR sensor surface via plasma polymerization of hexamethyldisiloxane. The working sensor surface was a 34 nm dielectric layer with immobilized bovine serum albumin (BSA) antigen and an adjacent thin 1 nm dielectric layer without BSA provided reference surface. A specific immunoreaction of anti-BSA antibody was detected after immersion of the SPR probe into sample solution. Simultaneous observation of reference and working surface response enabled determination of the immunoreaction without the need for the baseline measurement. Moreover, compensation of nonspecific adsorption could be confirmed using anti-human serum albumin antibody.

Antibodies↗